07:00 , Jul 1, 2013 |  BC Week In Review  |  Company News

AmideBio sales and marketing update

AmideBio launched its BioPure Amyloid-beta 1-42 peptide ( beta amyloid 42 ) in laboratory research quantities (50-1,000 µg) for use in Alzheimer's disease (AD) research. The company also markets laboratory research quantities of a number...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

ProScript management update

ProScript Inc., Cambridge, Mass.   Business: Autoimmune/Inflammation   Hired: Marlene Booth, as VP of project management, quality assurance and regulatory affairs; formerly senior director of regulatory affairs at Biopure Corp.   Hired: Stacey Channing, as...
07:00 , Jul 27, 2009 |  BC Week In Review  |  Company News

Biopure hematology news

Biopure filed for Chapter 11 bankruptcy. In connection with the filing, the company will sell substantially all of its assets, including Hemopure hemoglobin glutamer, to OPK Biotech LLC for $2.6 million plus up to $500,000...
07:00 , Jul 27, 2009 |  BC Week In Review  |  Financial News

Biopure financial update

Biopure received a letter from NASDAQ indicating the company's securities will be delisted on July 28 after filing for protection under Chapter 11 of the Bankruptcy Code. Biopure Corp. (Pink:BPURQ), Cambridge, Mass.   Business: Hematology...
07:00 , May 25, 2009 |  BC Week In Review  |  Clinical News

Hemopure hemoglobin glutamer: Phase IIb/III hold

Biopure said FDA placed a clinical hold on the U.S. Phase IIb/III RESUS trial, which was proposed by the Naval Medical Research Center (NMRC) and designed to enroll injured civilians. In 2006, an FDA committee...
07:00 , Mar 30, 2009 |  BC Week In Review  |  Clinical News

Hemoglobin glutamer: IND resubmitted

The Naval Medical Research Center (NMRC) submitted a revised protocol to FDA for the Phase IIb/III RESUS trial designed to enroll injured civilians in the U.S. In 2006, an FDA committee recommended against the proposed...
07:00 , Mar 23, 2009 |  BioCentury  |  Finance

Ebb & Flow

A proposal written by Washington attorney Leslie Platt that up to $50 billion of TARP money be invested in biotech and other innovation industries was based, in part, on Germany's BioRegio contest in 1996, which...
08:00 , Feb 23, 2009 |  BC Week In Review  |  Company News

Biopure hematology news

Biopure engaged Newbury Piret & Co. to explore strategic options including a financing or alternative transactions. Last October, South Africa's Medicines Control Council (MCC) withdrew marketing approval of Biopure's Hemopure hemoglobin glutamer to treat acute...
08:00 , Jan 5, 2009 |  BC Week In Review  |  Clinical News

Hemoglobin glutamer: IND hold

FDA placed a clinical hold on the Naval Medical Research Center 's proposed single-blind Phase II Op RESUS trial designed to compare Biopure's Hemopure vs. Hextend in 340 injured military personnel on the battlefield. The...
08:00 , Nov 3, 2008 |  BC Week In Review  |  Company News

Biopure hematology news

Biopure filed suit against NIH researcher Charles Natanson in the U.S. District Court for the District of Columbia. The suit alleges that Natanson made false and defamatory statements in an article in the Journal of...